Sera Prognostics (SERA) Competitors

Sera Prognostics (NASDAQ:SERA) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

Which has more risk and volatility, SERA or CODX?

Sera Prognostics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of -0.85, suggesting that its stock price is 185% less volatile than the S&P 500.

Do analysts prefer SERA or CODX?

Sera Prognostics currently has a consensus price target of $2.75, indicating a potential downside of 66.42%. Co-Diagnostics has a consensus price target of $2.00, indicating a potential upside of 48.15%. Given Co-Diagnostics' higher probable upside, analysts clearly believe Co-Diagnostics is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Co-Diagnostics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Is SERA or CODX more profitable?

Co-Diagnostics has a net margin of -582.36% compared to Sera Prognostics' net margin of -11,843.79%. Co-Diagnostics' return on equity of -42.35% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-11,843.79%	-46.35%	-36.31%
Co-Diagnostics	-582.36%	-42.35%	-38.55%

Do insiders and institutionals hold more shares of SERA or CODX?

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 15.8% of Sera Prognostics shares are owned by company insiders. Comparatively, 2.4% of Co-Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer SERA or CODX?

Co-Diagnostics received 263 more outperform votes than Sera Prognostics when rated by MarketBeat users. Likewise, 63.34% of users gave Co-Diagnostics an outperform vote while only 38.46% of users gave Sera Prognostics an outperform vote.

Company	Underperform	Outperform
Sera Prognostics	Outperform Votes 10 38.46%	Underperform Votes 16 61.54%
Co-Diagnostics	Outperform Votes 273 63.34%	Underperform Votes 158 36.66%

Does the media prefer SERA or CODX?

In the previous week, Sera Prognostics' average media sentiment score of 0.98 beat Co-Diagnostics' score of 0.00 indicating that Sera Prognostics is being referred to more favorably in the media.

Company	Overall Sentiment
Sera Prognostics	Positive
Co-Diagnostics	Neutral

Which has better earnings and valuation, SERA or CODX?

Co-Diagnostics has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$310K	862.59	-$36.24M	-$1.07	-7.65
Co-Diagnostics	$6.81M	6.20	-$35.33M	-$1.32	-1.02

Summary

Sera Prognostics beats Co-Diagnostics on 9 of the 17 factors compared between the two stocks.